HEPP News, Vol. 3 No. 4 by HIV Education Prison Project
University of Rhode Island
DigitalCommons@URI
Infectious Diseases in Corrections Report (IDCR)
2000
HEPP News, Vol. 3 No. 4
HIV Education Prison Project
Follow this and additional works at: http://digitalcommons.uri.edu/idcr
This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in
Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Recommended Citation
HIV Education Prison Project, "HEPP News, Vol. 3 No. 4" (2000). Infectious Diseases in Corrections Report (IDCR). Paper 14.
http://digitalcommons.uri.edu/idcr/14
HEPP
news
HIV 
EDUCATION
PRISON 
PROJECT
Sponsored by the Brown University School of Medicine Office of Continuing Medical Education and the Brown University AIDS Program.
Brown University School of Medicine       Providence, RI 02912       401.863.2180       fax: 401.863.1243       www.hivcorrections.org
April 2000  Vol. 3, Issue 4
HIV Infection Among Incarcerated Women:
An Epidemic Behind the Walls
ABOUT HEPP
HEPP News, a forum for 
correctional problem solving, 
targets correctional administrators
and HIV/AIDS care providers including
physicians, nurses, outreach workers,
and case managers. Published monthly
and distributed by fax, HEPP News 
provides up-to-the-moment infor-
mation on HIV treatment, efficient
approaches to administering HIV treat-
ment in the correctional environment,
national and international news related
to HIV in prisons and jails, and changes
in correctional care that impact 
HIV treatment.  Continuing Medical
Education credits are provided by the
Brown University Office of Continuing
Medical Education to physicians who
accurately respond to the questions on
the last page of the newsletter.  
EDITORS 
Anne S. De Groot, M.D.
Director, TB/HIV Research Lab,
Brown University School of Medicine
Frederick L. Altice, M.D.
Director, HIV in Prisons Program,
Yale University AIDS Program
Joseph Bick, M.D.
Chief Medical Officer,
HIV Treatment Services
California Department of Corrections
California Medical Facility, Vacaville
Faculty Disclosure 
In accordance with the Accreditation
Council for Continuing Medical Education
Standards for Commercial Support, 
the faculty for this activity have been
asked to complete Conflict of Interest
Disclosure forms. Disclosures are listed
at the end of articles. All of the individual
medications discussed in this newsletter
are approved for treatment of HIV unless
otherwise indicated. For the treatment of
HIV infection, many physicians opt to use
combination antiretroviral therapy which
is not addressed by the FDA.
HEPP News is grateful for the primary 
support of Agouron Pharmaceuticals and the
additional support of Roche Pharmaceuticals,
Merck, Roxane Laboratories, Dupont and
Bristol-Myers Squibb through unrestricted
educational grants.
Even though women are less likely to be incar-
cerated than men (one in 10 inmates in US pris-
ons and jails is a woman), incarcerated women
are three times more likely to be HIV infected than
incarcerated men. The proportion of inmates with
HIV (US prisons: 2.3% of men and 3.5% of
women) is much higher than the proportion of HIV
infected persons in the general population (US
free population: 0.6% of men, 0.1% of women).
This difference is amplified in the Northeast,
where HIV prevalence among incarcerated men
is 7% and 13% among incarcerated women.1
In addition, the number of HIV infected women in
prison has risen steadily since 1980, due in part
to the steady increase in the total number of
women who are incarcerated (figure 2).2 The
prevalence of HIV infection among incarcerated
women rose 88% in 1995, while the rate among
men rose 28% (figure 1).3
Why so much HIV among 
incarcerated women?
In most prison systems, the prevalence of HIV
among women is two- to three-fold higher than in
men. Numerous studies have shown that the
same behaviors that lead to incarceration put
women at increased risk for HIV infection.4,5,6,7
Links between drug use, sex work, victimization,
poverty, race and HIV explain the prevalence of
HIV infected women behind prison walls. Recent
reports on the status of women inmates in the US
have revealed the following:
l 84% of the total US female inmate population,
or 65,338 women, reported a history of "ever"
using drugs. 74% used drugs regularly.8
l Most of the 84,400 women who were in prison
in 1998 were incarcerated in state facilities
(63,735). 37% of state women inmates were
charged with drug-related offenses, while 72% of
women in federal prisons were charged with
drug-related offenses. Since 1980, the rate of
incarceration of women for drug charges has
increased three-fold, (11% to 34%), while the rate
of incarceration for violent offense has declined
by half (49% to 28%).9
l Almost two-thirds of women in prison are
women of color.10 Black women are twice as
likely as Hispanic women and eight times more
likely than White women to be in prison. HIV has
disproportionately impacted women of color in
recent years.11
l According to self reported data, between one
half and two thirds of incarcerated women have
been physically or sexually abused before incar-
ceration. These figures probably underestimate
the prevalence of such histories among incarcer-
ated women.12,13
Incarcerated women frequently report histories of
sexual and physical abuse. As many as two in
three incarcerated women (33-65%) report prior
sexual abuse and as many as two in five (19-
42%) report a history of childhood sexual
abuse.14,15 More than 80% of women in prison
have experienced significant and prolonged
exposure to physical abuse by family members or
intimates.16 In contrast, in studies of women who
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This graph describes the increase in HIV-infected
inmates by gender for each year between 1992 and
1997, compared to the 1991 baseline. The number
of HIV-infected incarcerated women has been rising
steadily while the number of HIV-infected men has
leveled off and appears to be declining. Adapted from
the GAO Report on Women in Prison, December 1999.
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are not currently incarcerated, approximately
one in seven women reported a history of
forced sex, one in five women (20%) report a
history of childhood sexual abuse, and about
one in four (25%) women report a history of
physical abuse. (Note that these studies of
women in "free living" communities did not
explore histories of incarceration, thus there
may be some overlap between the popula-
tions). The impact of prolonged sexual and
physical abuse prior to incarceration on incar-
cerated women’s health care, mental health
care, and risk behaviors is thought to be pro-
found.17,18
Incarceration represents an opportunity for
health care and mental health care that may
reduce the long-term sequelae of physical and
sexual abuse. Although unproven, it is likely
that selected interventions (such as HIV edu-
cation, sexual abuse recovery, mental health
care) in the appropriate setting may also
reduce HIV risk behavior among these high-
risk women after release from prison. For
those women that are already HIV infected,
incarceration represents an opportunity to ini-
tiate a comprehensive HIV care plan and to
build a framework for continuity of care that
extends to the community to which she will
return.
Management of the HIV- 
infected incarcerated woman
The life circumstances of this population, as
described above, are a critical reminder that
an HIV-infected incarcerated woman has
many concerns that affect her ability and will-
ingness to engage in the complex course of
intervention that is characteristic of effective
HIV treatment. An incarcerated woman’s
experiences and concerns are the framework
within which a provider must construct her HIV
management plan.
Making the diagnosis
Especially in state prison systems, there may
be elective or mandatory HIV testing at the
beginning or the end of incarceration. Most
systems allow elective testing when medically
indicated at any time during incarceration as
well. In prisons or jails where there is no
mandatory testing, the issue of convincing
female prisoners to be tested becomes very
important. When approached in a sensitive
manner, incarcerated women are often willing
to be tested for HIV. Factors that can encour-
age women to be tested include the impact of
HIV infection on their present or future children
and concerns about having acquired HIV
infection in the context of  other sexually trans-
mitted diseases. Many of these women may
have been tested in the course of prior preg-
nancies and may therefore be familiar with the
concepts and procedures related to perform-
ing the HIV test. However, younger women
(who have had fewer arrests, fewer pregnan-
cies, and may have had fewer opportunities
for interacting with HIV testers and coun-
selors) may be more resistant to testing. 
Given the high
prevalence of
HIV infection and
HIV risk behav-
iors among incar-
cerated women, it
is extremely
important to use
every opportunity
to discuss HIV
testing and to
promote safer
lifestyles. The fol-
lowing clinical sit-
uations indicate
HIV testing and
HIV education:
l Diagnosis of
another (non-
HIV) sexually
transmitted disease
l Requirement for detoxification after admis-
sion to jail (discussion of HIV risk and test is
recommended after the detoxification period
is over)
l History of treatment for a sexually transmit-
ted disease
l Presence of Hepatitis B or C infection (sug-
gesting other blood/sexually transmitted
infections may be present)
l History of sexual abuse (can be associated
with HIV risk behaviors)
l History of sex work19
l Request for pregnancy testing
The incarcerated woman’s fear of stigmatiza-
tion by her peers and by correctional staff has
a markedly negative impact on testing pro-
grams in prisons and jails. The closed setting
of correctional institutions makes confidential-
ity difficult to maintain (particularly if a clinic or
care provider is identified as being associated
with HIV). Peer education programs that
reduce stigmatization and increase the gener-
al awareness of HIV (and the prevalence of
infection among their peers) in the female
prison or jail population appear to have a pos-
itive impact on a woman’s willingness to be
tested.20
Initiating and Managing
Treatment
Once the diagnosis of HIV is made, clinicians
should discuss treatment with the patient. It is
becoming increasingly important to spend a
great deal of time educating patients prior to
initiating therapy. Some correctional facilities
for women schedule an initial discussion with
the HIV physician specialist, followed by an
additional one to two visits at two-week inter-
vals prior to the initiation of therapy. Clinicians
and patients should address timing of medica-
tion, special meal restrictions, and side effects
prior to instituting therapy. The physician or
nurse case manager should provide a written
description, in the appropriate language, of the
regimen, accompanied by pictures of the pills.
For illiterate patients, instructions that include
pictures of their pills accompanied by draw-
ings of clocks (showing dosing times) are usu-
ally very helpful. The patient should be asked
to recite the medication regimen from memory
at each visit. Incarcerated women are usually
ready partners, once treatment is initiated, and
exhibit better adherence while incarcerated
than has been reported among patients in the
community.21
Care of pregnant incarcerated
women
In 1998, 1,400 women gave birth within pris-
ons, but the number of those who were HIV
infected is unknown.22 The extent of prenatal
screening for HIV infection performed in feder-
al and state prisons is also unknown at this
time. Transmission of HIV infection to the fetus
has been all but eradicated in the US due to
the success of pre-natal HIV testing programs
in the community. However, leading pediatric
HIV researchers have raised concern about
reaching high risk women who seek care late
in the course of pregnancy.23
The correctional setting provides a critical
opportunity to reach a group of women who
may not have accessed pre-natal testing in
the community. Therefore, incarceration repre-
sents an opportunity to intervene, should
maternal HIV infection be diagnosed, and an
opportunity to teach women about the need
for HIV testing and treatment during future
pregnancies. According to standards set forth
by Centers for Disease Control and
Prevention,24 thorough and non-judgmental
discussion of HIV testing and antiretroviral
therapy is a required component of pre-natal
care. 
Management of HIV-infected
women in correctional settings:
Established guidelines
The high prevalence of HIV infection among
incarcerated women has had a dramatic
impact on the type of care provided in correc-
tional health units and on the cost of providing
that care. Health care budgets for womens
correctional facilities can be two-fold higher
than budgets for mens correctional facilities.
Those institutions that provide care for women
populations where HIV is highly prevalent rank
among the most expensive health care pro-
grams in the country.25
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Since 1980, the number of women in federal and state prisons has grown more
than six-fold. Adapted from the GAO Report on Women in Prison, December 1999.
Figure 2. 
Number of Female Inmates in Federal and State Prisons 1980-1998
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Dear Colleagues,
The high prevalence of HIV infection among incarcerated women in some correctional institu-
tions, particularly those located in Delaware, Pennsylvania, New Jersey, New York, Connecticut,
and Massachusetts, is a striking reminder of Jonathon Mann’s adage: HIV strikes hardest among
the most vulnerable populations. Linkages between histories of childhood sexual abuse, physical
abuse, drug use, sex work, and HIV risk behaviors are believed to explain the disproportionately
high prevalence of HIV infection among incarcerated women. Clearly, correctional institutions for
women provide a unique access point for interventions designed to reach high-risk women pop-
ulations. However, despite the critical position correctional institutions occupy in the AIDS epi-
demic, HIV prevention and management services are all too often considered onerous budgetary
and personnel burdens. 
Here I would like to take my prerogative, as HEPP News editor, to propose that we rethink this
situation. I propose that we, as correctional HIV providers, try to view our position at the nexus of
the AIDS epidemic as a distinct advantage. Correctional institutions for women have, at this point
in time, a unique opportunity to intervene by reducing HIV infection rates and diminishing the
impact of HIV on women who are already infected, their children, their family members, and the
communities to which they return. I would argue that efforts to contain or dramatically reduce HIV-
related expenditures in correctional facilities for women may be misplaced. Rather than attempt
to diminish the impact of the high prevalence of HIV in these populations on personnel effort, pro-
gramming needs, and medication expenditures, correctional institutions might benefit from seiz-
ing this opportunity for leadership and develop "centers of excellence" for HIV care of women. 
The good news is that some institutions for women have already taken this opportunity, and have
even been able to take advantage of public health funding streams to support their leadership
activities. Some of those programs (the list is incomplete) are summarized in this month’s
HEPPigram. When more institutions follow the example set by these leaders, and when their
efforts are given the support and recognition they deserve by the public sector, all members of
the correctional community, including the women who are affected, will benefit.
After reading this months HEPP News readers will be able to cite recent statistics and findings,
describe the linkage between histories of sexual abuse, drug use, and HIV infection among incar-
cerated women, describe the management of pap smears among incarcerated populations, and
list the components of existing models of HIV care for incarcerated women.
Please continue to send us feedback!
Sincerely,
Anne S. De Groot, M.D.
Letter from the Editor
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4Due to the recent increase in HIV patients
within corrections, some institutions have
developed flexible approaches to providing
medications that address women inmates’
needs. For example, women who are expect-
ed to be poor adherers can "graduate" to
keeping their medications on person if they
demonstrate adherence by attendance at the
medline window. In some other institutions, a
"strip pack" containing a one-day supply of
medication is provided. This diminishes med-
line staffing needs while allowing for monitor-
ing of medication and avoids the distribution of
excess medication. (Release of strip packs is
approved by a licensed doctor over the
phone.)
Weekend admissions, dietary requirements
and the timing of administration make adher-
ence to and continuity of medications formida-
ble tasks. One correctional facility for women
recently addressed the problem of weekend
admissions by making a three-day supply of
medications available in "contingency" for use
during weekends and extended holidays when
less experienced M.D.s are covering the HIV
infected patients.  
Continuity of access to medication after
release is addressed by providing a supply of
medication at discharge that is sufficient, in
theory, to cover the time period between
release from incarceration and the first clinic
visit post release. Some facilities provide a
thirty-day supply of medication at discharge,
recognizing how difficult it may be for women
to locate a place to live, to reconnect with their
families, and to attend to their medical needs
after release from prison or jail. In fact, dis-
charge planning programs have by now
become a widely accepted component of cor-
rectional HIV management, helping incarcer-
ated women make smoother transitions into
the community and continue to access HIV
medical and related services after incarcera-
tion. A number of innovative inmate release
plans have been devised to ensure continuity
of HIV care, such as the StadtRelease plan
formulated for various prison systems by a
national medication distributor, Stadtlanders.
Other states, like Georgia, have created simi-
lar plans with the assistance of a number of
ART drug manufacturers.
HIV education in correctional
settings
In recognition of the important role that HIV
education plays in the reduction of HIV risk
behaviors, many womens correctional facili-
ties offer an array of HIV and safer sex educa-
tion programs, peer led groups, drug treat-
ment, counseling, and vocational training pro-
grams for their incarcerated female popula-
tion. Bedford Hills in New York paved the way
for future and existing models of HIV care by
offering sexual and physical abuse recovery
as a component of its program, AIDS
Education and Counseling (ACE). 
Programs that provide basic understanding of
the virus, the disease, and build skills that
diminish HIV risk are critically important in cor-
rectional settings. Programs that include these
components have been published in detail.26
Providers and patients need to have the same
points of reference if the patient is ever to
understand concepts of bacteria and viruses.
Incarceration is also an excellent opportunity
to discuss risk reduction practices.27
Conclusion
Correctional management of HIV can be
viewed as a network of interconnected ser-
vices that can address the various needs of an
incarcerated woman infected with HIV. By test-
ing for HIV infection and screening for gyne-
cologic infections among incarcerated women,
correctional health care providers can play a
critical role in public health strategies for treat-
ing and reducing the spread of infectious dis-
eases. By diagnosing HIV and instituting a
plan for treatment, correctional facilities for
women can play a critically important role in
the reduction of morbidity and mortality among
HIV infected women in high risk populations.
By instituting comprehensive prenatal diagno-
sis and treatment protocols, correctional facili-
ties can reduce vertical transmission. By diag-
nosing and treating sexually transmitted dis-
eases, and using every sexually transmitted
infection as an opportunity to teach about HIV,
correctional facilities for women can reduce
susceptibility to HIV and may also reduce hor-
izontal transmission. 
Overall, incarceration provides a critical oppor-
tunity for the education, diagnosis, and med-
ical care of HIV-infected women and high-risk
HIV seronegative women. Education and
empowerment of these women who live with
HIV and who are at risk of HIV, will help reduce
their vulnerability. Above all, if we can address
their HIV care and engage them as partners in
an HIV management plan, it will not only ben-
efit the women as individuals, but also the
communities to which they may return.
HIV Infection... 
(continued from page 2)
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Donna Bell - Rikers Island Correctional Center, New York City
by Michelle Gaseau, Managing Editor, The Corrections Connection 
(www.corrections.com)
Working with pregnant inmates is a difficult job: the offenders often have multiple
medical complications, don’t understand the importance of proper medical care and
resist most suggestions to improve their health and that of their unborn children. At
Rikers Island, where Donna Bell, M.D. OB/GYN sees about 1,000 pregnant inmates
a year, HIV treatment and testing also plays a role in the care of these women.
HEPP News interviewed Dr. Bell about her work in 1999. 
HEPP News: What is your approach with pregnant inmates when they come to the
clinic?
Dr. Bell: Three days a week I provide obstetrical care and the other two days gyneco-
logical care. We might provide a colposcopy to find out why they might have an abnor-
mal pap. Most of our population is prostitutes and drug addicts. They trade sex for
drugs. They have all the Sexually Transmitted Diseases; warts is the biggest [dis-
ease]. We are mandated to test for and treat STDs and it is done on admission. If they
desire it, HIV testing is voluntary. Most of them don’t want it. The pregnant HIV-posi-
tive inmates we send to a counselor. We can’t make them take the test, but we sit
them in there with the counselor. We give it a try. I probably see about 1,000 inmates
a year, but we have only 100 deliveries a year. They range from 16 to 44 years old.
We try to send them to the city hospitals to deliver. We evaluate them in the clinic and
send them out. 
HN: What kind of testing and treatment is available to HIV-positive pregnant inmates?
DB: The fact that there are any resources at all is amazing. A lot of times the girls who
are HIV positive haven’t even had a viral load test. We did a blind study here where
25 to 30 percent were found to be HIV positive. CD4 testing is initiated here and the
inmates are connected to a liaison on the outside. A social worker will set them up
with HIV housing, social security, clinics on the outside, drug programs; they try to
streamline the paperwork for them. We also have a syphilis-testing program. If they
test positive then they are treated on the spot. That helps drop the syphilis numbers
way down. 
HN: How do you get pregnant inmates, including those who are HIV-positive, to partic-
ipate in medical care?
DB: Girls will test you and try to push you. They will try to harass you, they cajole you,
and they are hyperactive. You have to let them know you won’t be pushed around. I
argue with people all day long. When you get through all of that, you are doing the
same thing you are doing on the outside. We provide everything here. We try to do as
much here as we can. We have a high-risk pregnancy doctor who comes in. It’s very
hard and frustrating, but I always tell myself that a baby could someday be the
President of the United States. You never know.
HN: Are the pregnant inmates and new mother inmates housed separately at Rikers?
DB: They are segregated where there are pregnant and post-partum inmates. Every
third day they have prenatal classes. We have a nursery program here, [which they
participate in] if they pass a psych exam. We have about seven inmates in the nursery
now. They take care of their babies there and the babies can stay up to 18 months.
Inmates can conceivably be here six to 12 months.
HN: What is frustrating about your work?
DB: I wish there were some way to make them take advantage of the programs.
When they do utilize them, they do it to get out. I have girls who can be in [the jail]
four times during the same pregnancy. It’s ’Three hots and a cot.’ They don’t have a
job, they don’t have any skills, and they already have a record, so they come. [We] get
up to 35 girls a day. You never really know who you can make a difference with. 
HN: What is rewarding about your job?
DB: I’m definitely serving an underprivileged community. You have to yell and scream,
but once you get over that, they start to come to you and pay attention and go to pre-
natal classes. It’s nice to see them start to become real mothers. One of my patients
was bouncing off the walls when she came in. Of course she had a complicated preg-
nancy. They put her on medication and two months later she was transferred to
Bedford State Correctional Center. I received a letter from her after than and it was so
clear with insight. It was a page and a half letter. We sent a postcard back to her. I’m
proud to be here. I can work in other places outside, but I’m happy to be here.
New Drug Targets: 
Updates from the 7th Conference
on Retroviruses and Opportunistic
Infections
David Paar, M.D.*
At the 7th Conference on Retroviruses and
Opportunistic Infections, scientists identified new
targets for HIV medication development. Three
HIV-1 enzymes are necessary for viral replication:
reverse transcriptase, protease, and integrase.
Current antiretrovirals include nucleoside and non-
nucleoside reverse transcriptase inhibitors (NRTIs,
NNRTIs) and protease inhibitors (PIs). Identifying
effective inhibitors of HIV-1integrase, the enzyme
responsible for inserting viral DNA into the DNA of
host lymphocytes and macrophages, has chal-
lenged researchers for years. Integrase activity is
complex and requires at least three sequential
steps:  binding of integrase to viral DNA, process-
ing of viral DNA by the bound integrase, and,
insertion of the viral DNA into the host cell DNA.
Previously identified compounds that blocked steps
1 or 2 were not sufficient to stop viral replication in
tissue culture. Scientists have identified two new
compounds that block the third step in integrase
activity, and both inhibit HIV-1 replication in tissue
culture suggesting that they might be useful antivi-
ral drugs. Neither of these specific compounds
may pass the rigorous pre-clinical and clinical eval-
uations for safety and efficacy. However, identifica-
tion of the crucial step for integrase inhibition rep-
resents a significant advance in the search for a
clinically useful integrase inhibitor. (Session 22.
Symposium. New Drug Targets:  Integrase
Inhibitors).
Bushman, et al,  presented a study regarding the
identification of clinically useful RNAse H inhibitors.
Reverse transcriptase (RT) is another enzyme
whose function is a multistep process. After HIV-1
entry into a lymphocyte or macrophage, the DNA
polymerase activity of RT uses single-stranded
viral RNA as a template to produce double-strand-
ed viral DNA. Intermediate products of this process
are double-stranded RNA/DNA hybrids. Since only
double-stranded viral DNA can be integrated into
host cell DNA, the RNA portion of these hybrids
must be removed before double-stranded viral
DNA is produced. This is accomplished by the
RNAse H activity of reverse transcriptase, which
hydrolyzes the RNA template. Bushman et al have
identified several classes of compounds which
inhibit this RNAse function. Although all of the spe-
cific compounds tested so far are relatively weak
inhibitors and unsuitable for further development,
the identification of clinically useful RNAse H
inhibitors seems certain. An interesting aside is
that the three dimensional structure of RNAse H
inhibitors is very similar to that of integrase
inhibitors despite a lack of similarity in amino acid
sequences. Whether this similarity will translate
into compounds with both integrase and RNAse H
activity remains to be seen. (Presented by:  Frederic
Bushman, The Salk Inst.,La Jolla, CA; Daria Hazuda, Merck
Res. Labs.,West Point, PA; and Stuart LeGrice, NCI,
Frederick, MD)
*Speakers Bureau: Roche Pharmaceuticals
Treatment News
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HEPPigram
Summary of Standard of HIV Care for Incarcerated Women in Three Northeastern Prisons
Name & Location
Method of HIV testing
WOMEN INMATES (1998)
-Sentenced
-Awaiting trial
% known HIV+ women
inmates
HIV+ women under treatment
MEDICAL STAFF:
-Physicians
-Nurses
-Case Managers
-Language skills
Available HIV-related medical
services and treatment:
-On-site
-Off-site services
-Medications
On-site ob/gyn care
MEDICATION POLICY:
-Keep on person (KOP)
-Medline
-Provisions for continuity 
of Medications
RISK REDUCTION, EDUCA-
TIONAL AND SUPPORT 
SERVICES SUCH AS:
-HIV & safer sex education
-Peer support/education
-Physical & sexual abuse
recovery
-Drug treatment
-Mental health
-Skills building & 
vocational training
Discharge planning
Oversight-review by external
institution to ensure quality
care
York Correctional Institution,
Niantic, CT^
Voluntary
1200
840
360
9*
80-100
4 PT HIV specialists
2 nurses
1 case manager
2 M.D.s speak eng/spa
HIV & eye clinics, intermediate
care unit, viral load monitoring
UConn Medical Center
HAART
Gyn care, cyrosurgery, obstetric
care
Yes
Yes
2 week supply upon discharge
Yes
Yes
No
Yes
Yes
Yes
Project Transitional Case
Management (TLC)
Doe vs. Meechum-court man-
dated level of HIV care w/ DOC
oversight
Massachusetts Correctional
Institution at Framingham, MA^^
Voluntary
643
100-150 (county)
100-150
9-12%
40-60
2 PT HIV specialist (1 day each)
1 nurse 
nurse acts as CM
at least 1 eng/spa counselor
HIV & eye clinics, infirmary, viral
load monitoring
Lemuel Shattuck Hospital
HAART
Gyn clinic (2x/wk), colposcopy
Yes (revoked upon non-adherence)
Yes
1 week supply upon discharge
Services provided by CBO (Great
Brook Valley Health Center)
Yes
Yes
No
Yes
Yes
Yes (collaboration with Boston
University allows some women to
obtain degrees)
Discharge planning provide by
CMS and contractors (including
Great Brook Valley Health Center)
and is overseen by the DOC 
State appointed AIDS Task Force
Bedford Hills Correctional
Facility, Bedford Hills, NY^^
Voluntary 
800 (up to 900)
800
0
9**
60
1 PT HIV specialist (3x/wk)
nurse administrator
N/A
2 eng/spa M.D.s
HIV clinic, infirmary, viral load
monitoring
St. Agnes Hospital, and
Westchester Medical Center
HAART
Gyn care, colposcopy,
cryosurgery, prenatal care
Yes
Yes
30 day supply upon discharge &
Rx for additional 2 wks
Services provided by AIDS
Counseling & Education (ACE)
Yes
Yes
Yes
Yes
Yes
Yes
Discharge planning with parole
and community based health
agencies
DOH oversight body
Adapted from the Journal of Correctional Health Care, Fall 1998; 5(2): 150-151. Updated for HEPP News in March, 2000,
* intake seroprevalence is not equivalent to sentence seroprevalence due to release of unsentenced inmates** 9% seropositivity of women inmates
under custody at BHCF, 18% intake seroprevelance based on 1997 blind study of reception at all NY women’s correctional facilities 
HIV Pathogenesis,
Antiretrovirals, and Other
Selected Issues in HIV Disease
Management
April 19, Chicago, IL
April 25, San Francisco, CA
May dates TBA, Dallas, TX
and Washington, DC
Call: 415.561.6725
Fax: 415.561.6740
E-mail: cme@iasusa.org
Visit: www.iasusa.org
Sponsor: International AIDS Society  
HIV Prevention with 
Incarcerated Persons
A Public Health Training Network
Satellite Broadcast
April 27, 2000  1:00-3:00 PM EST
Call: 800.458.5231 or 
TTY 800.243.7012
Visit: www.cdcnpin.org/broadcast
Sponsor: CDC’s National 
Prevention Information Network
10th Annual Clinical Care
Options for HIV Symposium
May 4-5, 2000  
Scottsdale, AZ
Call: 888.391.3996
Fax: 508.528.7880
Email: registration@mail.medscape.com
Visit: http://hiv.medscape.com/
symposium2000
Sponsors: N.W. Univ. Medical
School Comprehensive AIDS
Center
Drug Use, HIV and Hepatitis:
Bringing it All Together 
May 7-10, 2000
Baltimore, MD 
Call: 877.565.3693
Fax: 301.565.3710 
www.chhatt.net/conference.html
Sponsors: CSAT of  SAMHSA,
NIDA of NIH, and the CDC.
HIV Prevention Strategies for
Incarcerated Populations
June 20, 2000
Central Maryland, MD 
Call: 410.328.8674
Fax: 410.328.9106
Email: sholland@
medicine.umaryland.edu
Fee: $20
Sponsors: Institute of Virology at
the University of Maryland at
Baltimore, AIDS Education &
Conference Center. Maryland
Department of Health & Mental
Hygiene, AIDS Administration. Mid-
Atlantic AIDS Education and
Training Center (AETC). Baltimore
STD/HIV Prevention Training
Center (PTC) 
Save the 
Dates
News Flashes
Results from the Women’s
Interagency HIV Study
The Women’s Interagency HIV Study (WIHS)
collected data on the baseline behaviors of
561 HIV seronegative and 2040 HIV seropos-
itive women.  Self-report interviews revealed
prevalence of various sexual and contracep-
tive behavior.  Women with HIV were less like-
ly to report heterosexual activity in the previ-
ous 6 months (65% HIV-positive, 76% HIV
negative). There was no differences in the
proportion of  women reporting vaginal or anal
sex, although women with HIV were less like-
ly to report cunnilingus (41% HIV positive,
70% HIV negative) and fellatio (48% HIV pos-
itive, 57% HIV negative). 63% of women with
HIV always used condoms during vaginal sex
(versus 28% HIV negative) with lower rates of
condom use reported during other sexual
activities. The study concluded that although
women with HIV exhibit lower levels of sexual
risk behavior than uninfected women, many
remain to be reached in terms of learning
about and adopting safer behaviors. (Wilson-
Tracey E, et al. AIDS-Hagerstown, 1999 April
1; 13(5): 591-598.)
Clinical Trials in Florida DOC
Come to the Spotlight
Recent media coverage has raised a previ-
ously dormant discussion concerning the
ethics of inmate participation in clinical trials
for HIV medication. Articles printed in the St.
Petersburg Times (FL) have made arguments
both for and against such trials. HEPP News
spoke with Dr. David Thomas, Assistant Chief
of Health Services of the Florida Department
of Corrections. "All of our inmates are in-
formed volunteers without coercion. The [St.
Petersburg Times] article cited one inmate on
abacavir who could not recall whether or not
he had been told about hypersensitivity
reactions. We have several levels of in-
ternal, external and Federal review.  We have
demonstrated this objectively on multiple
occasions. The Office of Health Services of
the Florida Department of Corrections permits
our inmates to engage in research opportuni-
ties with a world class investigator and from
this interaction fundamental scientific princi-
ples have emerged that have been published
internationally. We are satisfied that our
inmates are under no coercion, are truly
informed and are absolute volunteers with the
ability to remove themselves from any study at
any time without consequences." 
Reaching Long-Term Success in
the Treatment of HIV Infection
Joel E. Gallant, from the Johns Hopkins
University School of Medicine in Baltimore,
recently wrote in JAMA that expert care
should be given to designing an HIV treatment
regimen that will be fully followed and tolera-
ble. Without this required expertise, regimens
become less effective because of cross-resis-
tance between the three drug classes.
Genotypic and phenotypic resistance assays
can help determine an effective salvage regi-
men if cross-resistance occurs. Viral load test-
ing is now useful in determining a patient’s
status in relation to a CD4 cell count. It is up
to patients and qualified physicians to make
the best informed decisions in order to sup-
press viral load and prevent drug resistance.
(Gallant JE. JAMA. 3/08/00; 283(10): 1329.)
ART Dosing Update
The FDA has approved a new twice daily
dosing of Nelfinavir mesylate (1250 mg BID
5tablets) (Viracept, Agouron). The new tablets
feature a gel coating to facilitate admin-
istration. Also, delavirdine mesylate (Re-
scriptor, Agouron) is now available as a
200mg tablet, instead of 100mg, which cuts
the pill count in half and the new 200 mg pills
are two-thirds the size of the 100mg tablets. 
News from the National AIDS
Update Conference
The 12th Annual National AIDS Update
Conference was held in San Francisco,
California last month. While HIV in the correc-
tional setting was not discussed in any of the
plenary speeches, a number of workshops
addressed the current issues. At an intensive
workshop before the official opening of the
conference, four groups from California prison
projects presented insights into improving HIV
prevention, testing, counseling, and education
in prisons and jails. The presenters empha-
sized the importance of involving inmates and
ex-inmates in the education and counseling
aspects of HIV intervention programs
(Abstract 19).  In one of the conference work-
shops, John Miles of the CDC’s National
Center for HIV, STD and TB Prevention pre-
sented data showing the burden of disease
among inmates, emphasizing that 17% of the
current cases of HIV in this country are report-
ed from correctional facilities. Margaret Winter
of the National Prison Project at the ACLU
summarized the lawsuit involving Mississippi
Department of Corrections’ mandatory HIV
testing and HIV-status-based segregation.
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The increase in development and progression of cervical dysplasia is
believed to occur because HIV-infected women have decreased tumor sur-
veillance capacity because of their altered immunoregulatory mechanisms.
Therefore, management of pre-malignant lesions should be more interven-
tional than with non-immunocompromised patients. Studies of the overall
incidence of cervical cancer in HIV infected patients with squamous cell
lesions are on going and these recommendations may be modified (person-
al communication, S. Cu-Uvin, HERS Study).
In the prison or jail setting, a more interventional approach is favored
because 1) inmates do not necessarily remain in the correctional environ-
ment for prolonged periods; 2) should inmates be released to the commu-
nity they may not be living in stable circumstances, and 3) it is unlikely that
the individual will have her gynecologic issues addressed in the communi-
ty while facing issues such as securing stable housing, meeting basic
needs, providing for children and addressing issue related to treatment of
her HIV/AIDS.  Thus, for women in the correctional setting who have squa-
mous cell lesions, it is prudent to go directly to colposcopy with directed
biopsy and offer treatment if necessary.  Source: Puisis M. Clinical Practice in
Correctional Medicine.  D.O. Mosby: St. Louis, IL, 1998.
HIV-infected incarcerated women have particularly high rates of cervical
cytological abnormalities, sexually transmitted diseases and certain gyne-
cologic infections. Research indicates that vaginal infections are slightly
more common among HIV-infected incarcerated women than HIV-nonin-
fected incarcerated women, while the prevalence rates of STDs are high
among incarcerated women compared to free-living women overall. 
High rates of syphilis among incarcerated women nationwide have prompt-
ed a number of studies assessing methods of syphilis screening and treat-
ment in the correctional setting. Several studies have shown the efficacy of
administering qualitative (or STAT) rapid plasma regain (RPR) testing for
syphilis.  A recent study conducted at a New York City jail found that quali-
tative nontreponemal syphilis testing (STAT RPR), on line access to the
local syphilis registry and immediate treatment (if indicated) following
admission medical evaluation increased syphilis treatment from 7% to 84%.  
Furthermore, high rates of HPV infection, of cervical cytological abnormali-
ties and of invasive cervical cancer have been found among high-risk HIV-
seronegative women and HIV-infected incarcerated women. Most correc-
tional HIV programs have adopted an increased level of vigilance for cervi-
cal cancer, leading to the institution of biannual pap smears (every six
months) as a routine component of care for HIV infected women. (See HIV
101 for more information)
Since many incarcerated women have experienced childhood sexual abuse
and adult sexual trauma, gynecological and obstetric examination takes
special care and sensitivity. Some of the issues that may interfere with the
examination of sexually abused women include their need to trust the
examiner, their need for control (wishing to control the time and place of the
gyn exam), their fear of disclosure, and their fear of having their body
touched during the examination. Insensitive gynecological providers can
become a major barrier to obtaining the routine gynecological screening
that is so critically important for this high risk population. Sensitive gyn
providers should be considered critical members of the correctional HIV
management team.
H
IV
 
1
0
1
Journal of the Association of Nurses in AIDS Care (JANAC)
is an excellent resource for care providers who work with HIV infected
patients. There are chapters of the association in most states. The
November/December 1999 issue focused on HIV policy and care in
correctional facilities.  The journal can be obtained from Sage
Publications, Inc. or via ANAC Dept.203, Washington DC 20055-0203
Women-Specific Websites:
Medscape: Women and HIV
http://hiv.medscape.com/medscape/hiv/clinicalmgmt/cm.v09/public/ind
ex-cm.v09.html
The Body: Women Specific HIV Treatment Issues
http://www.thebody.com/treat/women.html
Journal of the American Medical Association Women’s Health
Information Center
http://www.ama-assn.org/special/womh/womh.htm
HIV TREATMENT WEBSITES:
HIV/AIDS Treatment Directory 
http://www.amfar.org/td
Medscape HIV/AIDS
http://hiv.medscape.com
Johns Hopkins AIDS Service
http://www.hopkins-AIDS.edu
JAMA HIV/AIDS Information Center
http://www.ama-assn.org/special/hiv
International Association of Physicians in AIDS Care (IAPAC)
http://www.iapac.org
AEGIS-AIDS Education Global Information System
http://www.aegis.com
Resources
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Cervical cytology performed Q 6-12 months
Unsatisfactory for
evaluation
Repeat now Infection or inflam-matory
Colposcopy with
directed biopsy
Treat according to
diagnosis
Repeat cytology in
3 months
Dysplasia 1. Gynecology 
consultation
2. Ablative therapy
Repeat cervical
cytology in 6
months
No dysplasia
Repeat annually.
Repeat Q 6
months for all HIV
infected patients
and if there is a
history of 
anogenital HPV
infection or SIL
1. Atypical squamous
cells of undetermined
significance (ASCUS)
2. Low Grade squa-
mous intraepithelial
lesions (LGSIL)
3. High grade squa-
mous intraepithelial
lesions (HGSIL)
Within normal
limits
Benign cellular
changes
Epithelial cell
abnormalities
HIV 101 Gynecologic Care: An Integrated Component of HIV Care
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
May  31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. What are the latest targets for HIV medication development?
a) single-stranded viral RNA
b) double stranded RNA/DNA hybrids
c) HIV 1 integrase
d) reverse transciptase
e) none of the above
2. What proportion of women inmates report a history of child-
hood sexual abuse?
a) 10%
b) 20%
c) over 1/4
d) up to 1/3
e) up to 2/3
3. Indicate true or false.
Once treatment is initiated, incarcerated women show better 
adherence than patients in the community.
In most prison systems, the prevalence of HIV among 
women is two to three-fold higher than among men.
The Centers for Disease Control states that thorough 
discussion of HIV testing and antiretroviral therapy is a 
required component of standard pre-natal care.
4. Correctional facilities in Niantic, CT, Framingham, MA, and
Bedford Hills, NY have an average patient to HIV specialist ratio
of:
a) 1:30
b) 1:60
c) 2:100
d) 1:100
5. Cervical Cytology should be performed every 6 months on
patients with which of the following conditions?
a) history of anogenital HPV infection
b) history of SIL
c) HIV infection
d) a and b
e) a and c
f) all of the above
6. Which protease inhibitor dosing schedules are correct?
a) Amprenavir- 800mg BID
b) Nelfinavir- 1250mg BID
c) Ritonavir- 600mg TID
d) Saquinavir- 600mg BID 
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Spotlight 5  4  3  2  1   5  4  3  2  1   
Save the 5  4  3  2  1   5  4  3  2  1   
Dates
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific  comments on this issue?
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